BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 20493777)

  • 1. Human cytomegalovirus-specific CD4(+) and CD8(+) T-cell response determination: comparison of short-term (24h) assays vs long-term (7-day) infected dendritic cell assay in the immunocompetent and the immunocompromised host.
    Zelini P; Lilleri D; Comolli G; Rognoni V; Chiesa A; Fornara C; Locatelli F; Meloni F; Gerna G
    Clin Immunol; 2010 Aug; 136(2):269-81. PubMed ID: 20493777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human cytomegalovirus-specific CD4+ and CD8+ T cell responses in primary infection of the immunocompetent and the immunocompromised host.
    Lilleri D; Zelini P; Fornara C; Comolli G; Revello MG; Gerna G
    Clin Immunol; 2009 Jun; 131(3):395-403. PubMed ID: 19268633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
    Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
    Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of human cytomegalovirus-specific T lymphocytes in human blood: comparison of two methods.
    Schermann CM; Fischer G; Witt V; Kurz M; Potschger U; Fritsch G
    Cytotherapy; 2008; 10(8):834-41. PubMed ID: 19016371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
    Fleming T; Dunne J; Crowley B
    J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of human cytomegalovirus (HCMV) T-cell response in the control of HCMV infection by seropositive solid-organ transplant recipients according to different assays and stimuli.
    Gabanti E; Bruno F; Scaramuzzi L; Mangione F; Zelini P; Gerna G; Lilleri D
    New Microbiol; 2016 Oct; 39(4):247-258. PubMed ID: 27727404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.
    Peggs KS; Mackinnon S
    Hum Immunol; 2004 May; 65(5):550-7. PubMed ID: 15172456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous quantification of human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells.
    Lozza L; Lilleri D; Percivalle E; Fornara C; Comolli G; Revello MG; Gerna G
    Eur J Immunol; 2005 Jun; 35(6):1795-804. PubMed ID: 15902686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human cytomegalovirus-specific T cell reconstitution in young patients receiving T cell-depleted, allogeneic hematopoietic stem cell transplantation.
    Lilleri D; Gerna G; Fornara C; Chiesa A; Comolli G; Zecca M; Locatelli F
    J Infect Dis; 2009 Mar; 199(6):829-36. PubMed ID: 19239337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human cytomegalovirus-specific memory CD8+ and CD4+ T cell differentiation after primary infection.
    Lilleri D; Fornara C; Revello MG; Gerna G
    J Infect Dis; 2008 Aug; 198(4):536-43. PubMed ID: 18590456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation.
    Eid AJ; Brown RA; Hogan WJ; Lahr BD; Eckel-Passow JE; Litzow MR; Razonable RR
    Transpl Infect Dis; 2009 Dec; 11(6):519-28. PubMed ID: 19744286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
    Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D
    Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of human cytomegalovirus infection in transplantation: validation of virologic cut-offs for preemptive therapy and immunological cut-offs for protection.
    Gerna G; Lilleri D; Furione M; Baldanti F
    New Microbiol; 2011 Jul; 34(3):229-54. PubMed ID: 21811744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normalizing ELISPOT responses to T-cell counts: a novel approach for quantification of HCMV-specific CD4(+) and CD8(+) T-cell responses in kidney transplant recipients.
    Calarota SA; Chiesa A; Scaramuzzi L; Adzasehoun KM; Comolli G; Mangione F; Esposito P; Baldanti F
    J Clin Virol; 2014 Sep; 61(1):65-73. PubMed ID: 24961915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease.
    Bronke C; Palmer NM; Jansen CA; Westerlaken GH; Polstra AM; Reiss P; Bakker M; Miedema F; Tesselaar K; van Baarle D
    J Infect Dis; 2005 Mar; 191(6):873-80. PubMed ID: 15717261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow cytometric analysis of virus-specific T lymphocytes: practicability of detection of HCMV-specific T lymphocytes in whole blood in patients after stem cell transplantation.
    Buxbaum S; Kraus FB; Hahn A; Beck O; Kabartas B; Doerr HW; Ludwig B
    J Immunol Methods; 2006 Apr; 311(1-2):164-73. PubMed ID: 16530782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of cytotoxic T lymphocytes specific for human cytomegalovirus using dendritic cells in vitro.
    Cho HI; Han H; Kim CC; Kim TG
    J Immunother; 2001; 24(3):242-9. PubMed ID: 11394502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire.
    Nastke MD; Herrgen L; Walter S; Wernet D; Rammensee HG; Stevanović S
    Cell Mol Life Sci; 2005 Jan; 62(1):77-86. PubMed ID: 15619009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
    Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
    J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation.
    Peggs KS; Verfuerth S; Pizzey A; Chow SL; Thomson K; Mackinnon S
    Clin Infect Dis; 2009 Dec; 49(12):1851-60. PubMed ID: 19911966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.